Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Oct. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0652964/Type-1-Diabetes-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Type 1 Diabetes Therapeutics market. The report identifies the key trends shaping and driving the global Type 1 Diabetes Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Type 1 Diabetes Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Type 1 Diabetes Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Type 1 Diabetes Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Type 1 Diabetes Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Type 1 Diabetes Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Type 1 Diabetes Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Type 1 Diabetes Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Type 1 Diabetes Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Type 1 Diabetes Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Type 1 Diabetes Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 8
2.4 Signs and Symptoms 9
2.5 Commonly Used Diagnostic Tests 10
2.6 Treatment and Management Options for Type 1 Diabetes 11
2.6.1 Types of Insulin 11
2.7 GlobalData Pipeline Report Guidance 13
3 Type 1 Diabetes Therapeutics - Market Characterization 14
3.1 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Global 14
3.2 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Global 15
3.3 Type 1 Diabetes Therapeutics Market Size (2005-2010) - The US 17
3.4 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - The US 18
3.5 Type 1 Diabetes Therapeutics Market Size (2005-2010) - France 19
3.6 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - France 20
3.7 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Germany 21
3.8 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Germany 22
3.9 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Italy 23
3.10 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Italy 24
3.11 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Spain 25
3.12 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Spain 26
3.13 Type 1 Diabetes Therapeutics Market Size (2005-2010) - The UK 27
3.14 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - The UK 28
3.15 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Japan 29
3.16 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Japan 30
3.17 Drivers and Barriers for the Type 1 Diabetes Therapeutics Market 31
3.17.1 Drivers for the Type 1 Diabetes Therapeutics Market 31
3.17.2 Barriers for the Type 1 Diabetes Therapeutics Market 32
3.18 Opportunity and Unmet Need Analysis 32
3.19 Key Takeaway 33
4 Type 1 Diabetes Therapeutics - Competitive Assessment 34
4.1 Overview 34
4.2 Strategic Competitor Assessment 34
4.3 Product Profiles for the Major Marketed Products in the Type 1 Diabetes Therapeutics Market 35
4.3.1 Apidra (insulin glulisine) 35
4.3.2 Humalog (insulin lispro) 37
4.3.3 Novolog (insulin aspart) 39
4.3.4 Lantus (insulin glargine) 40
4.3.5 Levemir (insulin detemir) 43
4.3.6 Symlin (pramlintide acetate) 44
4.4 Key Takeaway 45
5 Type 1 Diabetes Mellitus Therapeutics - Pipeline Assessment 46
5.1 Overview 46
5.2 Strategic Pipeline Assessment 46
5.3 Type 1 Diabetes Therapeutics Pipeline - Pipeline by Phases of Development 47
5.3.1 Type 1 Diabetes Therapeutics - Phase III Pipeline 47
5.3.2 Type 1 Diabetes Therapeutics - Phase II Pipeline 48
5.3.3 Type 1 Diabetes Therapeutics - Phase I Pipeline 49
5.3.4 Type 1 Diabetes Therapeutics - Pre-Clinical Pipeline 50
5.3.5 Type 1 Diabetes Therapeutics - Discovery 50
5.3.6 Technology Trends Analytic Framework 51
5.4 Type 1 Diabetes Therapeutics Market - Pipeline by Mechanism of Action 52
5.5 Type 1 Diabetes Therapeutics - Promising Drugs in Clinical Development 53
5.6 Molecule Profile for Promising Drugs in Clinical Development 53
5.6.1 Degludec (NN1250) 53
5.6.2 DiaPep277 54
5.6.3 Generex Oral-lyn 55
5.7 Others Drugs Profile in Clinical Development 56
5.7.1 Afrezza (insulin human [rDNA origin]) 56
5.7.2 Diamyd 57
5.7.3 Linjeta (formerly known as VIAject) 58
5.7.4 Otelixizumab 59
5.7.5 Teplizumab 60
5.8 Key Takeaway 60
6 Type 1 Diabetes Therapeutics - Clinical Trial Mapping 61
6.1 Clinical Trials by Region and Country 61
6.2 Clinical Trials by Phase 62
6.3 Clinical Trials by Trial Status 63
6.4 Clinical Trial Mapping by Sponsors 64
6.5 Prominent Sponsors 65
6.6 Top Companies Participating in Type 1 Diabetes Therapeutics Clinical Trials 66
7 Type 1 Diabetes Therapeutics - Strategic Assessment 67
7.1 Key Events Impacting the Future Market 67
7.2 Type 1 Diabetes Therapeutics: Implications for Future Market Competition 68
8 Type 1 Diabetes Therapeutics - Future Players 69
8.1 Introduction 69
8.2 Company Profiles 69
8.2.1 BioDelivery Sciences International, Inc 69
8.2.2 Diamyd Medical AB 70
8.2.3 Evotec Aktiengesellschaft 71
8.2.4 GlaxoSmithKline plc 72
8.2.5 Generex Biotechnology Corporation 73
8.2.6 Halozyme Therapeutics, Inc. 74
8.2.7 MacroGenics, Inc. 75
8.2.8 MannKind Corporation 76
8.2.9 Novo Nordisk A/S 77
8.2.10 Other Companies in the Type 1 Diabetes Therapeutics Market 78
9 Type 1 Diabetes Therapeutics - Licensing and Partnership Deals 79
10 Type 1 Diabetes Therapeutics - Appendix 96
10.1 Market Definitions 96
10.2 Abbreviations 96
10.3 Methodology 97
10.3.1 Coverage 97
10.3.2 Secondary Research 97
10.3.3 Forecasting 98
10.3.4 Primary Research 100
10.3.5 Expert Panel Validation 101
10.4 Contact Us 101
10.5 Disclaimer 101
10.6 Bibliography 102
List of Tables
Table 1: Recommended Diagnostic Test for Diabetes Mellitus 10
Table 2: Plasma Blood Glucose and A1C Goals for Type 1 Diabetes By Age Group 10
Table 3: Types of Insulin Preparations 12
Table 4: Type 1 Diabetes Therapeutics Market, Global, Revenue ($m), 2005-2010 14
Table 5: Type 1 Diabetes Therapeutics Market, Global, Forecast ($m), 2010-2018 16
Table 6: Type 1 Diabetes Therapeutics Market, The US, Revenue ($m), 2005-2010 17
Table 7: Type 1 Diabetes Therapeutics Market, The US, Forecasts ($m), 2010-2018 19
Table 8: Type 1 Diabetes Therapeutics Market, France, Revenue ($m), 2005-2010 19
Table 9: Type 1 Diabetes Therapeutics Market, France, Forecasts ($m), 2010-2018 20
Table 10: Type 1 Diabetes Therapeutics Market, Germany, Revenue ($m), 2005-2010 21
Table 11: Type 1 Diabetes Therapeutics Market, Germany, Forecasts ($m), 2010-2018 22
Table 12: Type 1 Diabetes Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Table 13: Type 1 Diabetes Therapeutics Market, Italy, Forecasts ($m), 2010-2018 24
Table 14: Type 1 Diabetes Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Table 15: Type 1 Diabetes Therapeutics Market, Spain, Forecasts ($m), 2010-2018 26
Table 16: Type 1 Diabetes Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Table 17: Type 1 Diabetes Therapeutics Market, The UK, Forecasts ($m), 2010-2018 28
Table 18: Type 1 Diabetes Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Table 19: Type 1 Diabetes Therapeutics Market, Japan, Forecasts ($m), 2010-2018 30
Table 20: Apidra - Efficacy Result of 26 Week Study Comparing Apidra with Insulin Lispro, 2011 35
Table 21: Apidra - Efficacy Result of 26 Week Study Comparing Apidra with Regular Insulin, 2011 36
Table 22: Apidra - Adverse Reactions Observed in Pooled Studies in Type 1 Diabetic Adults, 2011 36
Table 23: Type 1 Diabetes Therapeutics Market, Humalog, Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Month Cross Over Studies, 2011 37
Table 24: Humalog - Results of a Two Month Study Comparing the Use of Humalog and Humulin With Sulfonyluria (SU) Therapy, 2011 38
Table 25: Type 1 Diabetes Therapeutics Market, Novolog, Glycemic Parameters at the End of 24 Week Study, 2011 39
Table 26: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Efficacy, 2011 41
Table 27: Type 1 Diabetes Therapeutics Market, Lantus, Adverse Events in 28 Week Clinical Trials of Adults and Children With Type 1 Diabetes, 2011 41
Table 28: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Safety, 2011 42
Table 29: Levemir - Efficacy Result in 16 Week Non Blinded Study, 2011 43
Table 30: Type 1 Diabetes Therapeutics - Phase III Pipeline, 2011 47
Table 31: Type 1 Diabetes Therapeutics - Phase II Pipeline, 2011 48
Table 32: Type 1 Diabetes Therapeutics - Phase I Pipeline, 2011 49
Table 33: Type 1 Diabetes Therapeutics - Pre-Clinical Pipeline, 2011 50
Table 34: Type 1 Diabetes Therapeutics - Discovery, 2011 50
Table 35: Type 1 Diabetes Therapeutics - Most Promising Drugs in Clinical Development, 2011 53
Table 36: Type 1 Diabetes Therapeutics - Clinical Trials by Country, 2011 61
Table 37: Type 1 Diabetes Therapeutics - Clinical Trials by Phase, 2011 62
Table 38: Type 1 Diabetes Therapeutics - Clinical Trials by Status, 2011 63
Table 39: Type 1 Diabetes Therapeutics - Overall Sponsors, 2011 64
Table 40: Type 1 Diabetes Therapeutics - Prominent Sponsors, 2011 65
Table 41: Type 1 Diabetes Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 66
Table 42: BioDelivery Sciences International, Inc.– Type 1 Diabetes, Pipeline, 2011 70
Table 43: Diamyd Medical AB – Type 1 Diabetes, Pipeline, 2011 71
Table 44: Evotec – Metabolic Disorder, Pipeline, 2011 72
Table 45: GlaxoSmithKline plc – Metabolic Disorder, Pipeline, 2011 73
Table 46: Generex Biotechnology Corporation–Metabolic Disorder, Pipeline, 2011 74
Table 47: Halozyme Therapeutics–Metabolic Disorder, Pipeline, 2011 75
Table 48: Halozyme Therapeutics–Metabolic Disorder, Pipeline, 2011 75
Table 49: MannKind Corporation –Metabolic Disorder, Pipeline, 2011 76
Table 50: Novo Nordisk A/S – Type 1 Diabetes, Pipeline, 2011 77
Table 51: Type 1 Diabetes Therapeutics Market – Future Players 78
Table 52: Type 1 Diabetes–Global, Deals, 2011 79
List of Figures
Figure 1: Pathogenesis of Type 1 Diabetes 8
Figure 2: Type 1 Diabetes Therapeutics Market, Global, Revenue ($m), 2005-2010 14
Figure 3: Type 1 Diabetes Therapeutics Market, Global, Forecast ($m), 2010-2018 16
Figure 4: Type 1 Diabetes Therapeutics Market, The US, Forecast ($m), 2005-2010 17
Figure 5: Type 1 Diabetes Therapeutics Market, The US, Forecasts ($m), 2010-2018 18
Figure 6: Type 1 Diabetes Therapeutics Market, France, Revenue ($m), 2005-2010 19
Figure 7: Type 1 Diabetes Therapeutics Market, France, Forecast ($m), 2010-2018 20
Figure 8: Type 1 Diabetes Therapeutics Market, Germany, Revenue ($m), 2005-2010 21
Figure 9: Type 1 Diabetes Therapeutics Market, Germany, Forecast ($m), 2010-2018 22
Figure 10: Type 1 Diabetes Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Figure 11: Type 1 Diabetes Therapeutics Market, Italy, Forecast ($m), 2010-2018 24
Figure 12: Type 1 Diabetes Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Figure 13: Type 1 Diabetes Therapeutics Market, Spain, Forecast ($m), 2010-2018 26
Figure 14: Type 1 Diabetes Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Figure 15: Type 1 Diabetes Therapeutics Market, The UK, Forecast ($m), 2010-2018 28
Figure 16: Type 1 Diabetes Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Figure 17: Type 1 Diabetes Therapeutics Market, Japan, Forecasts ($m), 2010-2018 30
Figure 18: Opportunity and Unmet Need in the Type 1 Diabetes Therapeutics Market 33
Figure 19: Type 1 Diabetes Therapeutics - Strategic Competitor Assessment, 2011 35
Figure 20: Type 1 Diabetes Therapeutics - Pipeline by Phase of Development, 2011 47
Figure 21: Type 1 Diabetes Therapeutics - Technology Trends Analytics Framework, 2011 51
Figure 22: Type 1 Diabetes Therapeutics - Pipeline by Mechanism of Action, 2011 52
Figure 23: Type 1 Diabetes Therapeutics - Clinical Trials by Country, 2011 61
Figure 24: Type 1 Diabetes Therapeutics - Clinical Trials by Phase, 2011 62
Figure 25: Type 1 Diabetes Therapeutics - Clinical Trials by Status, 2011 63
Figure 26: Type 1 Diabetes Therapeutics - Overall Sponsors, 2011 64
Figure 27: Type 1 Diabetes Therapeutics - Prominent Sponsors, 2011 65
Figure 28: Type 1 Diabetes Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 66
Figure 29: Type 1 Diabetes Therapeutics Market, Drivers and Barriers, 2011 67
Figure 30: Implications for Future Market Competition in the Type 1 Diabetes Market, 2011 68
Figure 31: Type 1 Diabetes Therapeutics Market - Pipeline by Company, 2011 69
Figure 32: GlobalData Market Forecasting Model 100
Companies Mentioned
BioDelivery Sciences International, Inc
Diamyd Medical AB
Evotec Aktiengesellschaft
GlaxoSmithKline plc
Generex Biotechnology Corporation
Halozyme Therapeutics, Inc.
MacroGenics, Inc.
MannKind Corporation
Novo Nordisk A/S
To order this report:
Pathology Industry: Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Pathology Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article